血液分析是临床诊断的基础之一。近年来，质谱法分析血液样品中的蛋白质在灵敏度和鉴定蛋白质数量方面有了飞跃。最近发展的并行反应监测与并行累积串联断裂(prm-PASEF)将离子迁移作为一种额外的分离维度。这增加了蛋白质组的覆盖范围，同时允许使用更短的色谱梯度。为了展示该方法的全部潜力，我们使用了782个同位素标记的合成肽混合物，其中包括来自579个血浆蛋白的肽段，将其掺入血浆样本中，并使用prm-PASEF测量技术，通过定向蛋白质组学量化了565个血浆蛋白。作为prm-PASEF方法的一个耗时较少的替代方法，我们描述了引导数据无关采集 (dia)-PASEF (g-dia-PASEF)的应用，并将其与prm-PASEF方法应用于血浆测量进行比较。为了展示这两种方法在临床样本中的性能，我们分析了来自结直肠癌(CRC)队列的20个患者血浆样本。分析鉴定了14种不同调节的蛋白质，表明该技术具有快速和无偏差筛选血液蛋白的潜力，消除了对潜在生物标志物蛋白质的预先筛选的需求。

Blood analysis is one of the foundations of clinical diagnostics. In recent years, the analysis of proteins in blood samples by mass spectrometry has taken a jump forward in terms of sensitivity and the number of identified proteins. The recent development of parallel reaction monitoring with parallel accumulation and serial fragmentation (prm-PASEF) combines ion mobility as an additional separation dimension. This increases the proteome coverage while allowing the use of shorter chromatographic gradients. To demonstrate the method's full potential, we used an isotope-labeled synthetic peptide mix of 782 peptides, derived from 579 plasma proteins, spiked into blood plasma samples with a prm-PASEF measurement allowing the quantification of 565 plasma proteins by targeted proteomics. As a less time-consuming alternative to the prm-PASEF method, we describe guided data independent acquisition (dia)-PASEF (g-dia-PASEF) and compare its application to prm-PASEF for measuring blood plasma. To demonstrate both methods' performance in clinical samples, 20 patient plasma samples from a colorectal cancer (CRC) cohort were analyzed. The analysis identified 14 differentially regulated proteins between the CRC patient and control individual plasma samples. This shows the technique's potential for the rapid and unbiased screening of blood proteins, abolishing the need for the preselection of potential biomarker proteins.